Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 7, 2010, Pages 1292-1297

  Miriovsky, Benjamin J ^a   Michaud, Kaleb ^a   Thiele, Geoffrey M ^a   O'Dell, James R ^a   Cannon, Grant W ^b   Kerr, Gail ^c,d   Richards, J Steuart ^c,d   Johnson, Dannette ^e   Caplan, Liron ^b   Reimold, Andreas ^f   Hooker, Roderick ^f   Mikuls, Ted R ^a  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Sci Technol Med Div Congr R   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOXYCYCLINE; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADJUSTMENT; AGED; ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DISEASE ACTIVITY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNITED STATES; VETERAN; BLOOD; HOSPITALIZATION; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PROGNOSIS; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT SELECTION; PEPTIDES, CYCLIC; PROGNOSIS; REMISSION INDUCTION; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77955000386     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.122739     Document Type: Article

References (27)

1. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Raptopoulou A, Sidiropoulos P, Katsouraki M, et al. Anti-citrulline antibodies in the diagnosis and prognosis of rheumatoid arthritis: evolving concepts. Crit Rev Clin Lab Sci 2007;44:339-63.
3. Klippel JH, ed. Primer on the rheumatic diseases. 12th edn. Atlanta: Arthritis Foundation, 2001.
4. Turesson C, Jacobsson LTH, Sturfelt G, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007;66:56-64.
5. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
6. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51.
7. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
8. Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
9. Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
10. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
11. Rönnelid J, Wick MC, Lampa J, et al. Longitudinal analysis of citrullinated protein/ peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64:1744-9.
12. del Val del Amo N, Ibanez Bosch R, Fito Manteca C, et al. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006;24:281-6.
13. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-17.
14. Lee DM, Phillips R, Hagan EM, et al. Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:201-8.
15. Weyand CM, Schmidt D, Wagner U, et al. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum 1998;41:817-22.
16. Jawaheer D, Lum RF, Gregersen PK, et al. Influence of male sex on disease phenotype in familial rheumatoid arthritis. Arthritis Rheum 2006;54:3087-94.
17. Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther 2009;11:R7.
18. Mikuls TR, Kazi S, Cipher D, et al. The association of race and ethnicity with disease expression in male US veterans with rheumatoid arthritis. J Rheumatol 2007;34:1480-4.
19. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol 2005;32:1432-9.
20. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
21. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
22. Forslind K, Ahlmén M, Eberhardt K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
23. Kastbom A, Strandberg G, Lindroos A, et al. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
24. Mikuls TR, Saag KG, Criswell LA, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002;61:994-9.
25. Mandl LA, Costenbader KH, Simard JF, et al. Is birthweight associated with risk of rheumatoid arthritis? Data from a large cohort study. Ann Rheum Dis 2009;68:514-8.
26. Bos WH, Bartelds GM, Wolbink GJ, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008;35:1972-7.
27. Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-82.